TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Vimian Group AB ( (SE:VIMIAN) ).
Vimian Group AB has appointed Alireza Tajbakhsh as its new CEO, effective immediately. Tajbakhsh, who has been with Vimian since 2021, previously led the Veterinary Services segment and served as interim Head of the MedTech segment. His leadership is expected to continue driving the company’s strategy of organic and acquisition-driven growth, enhancing its position in the animal health industry. The appointment is seen as a strategic move to strengthen Vimian’s global leadership in animal health niches with unmet medical needs, aiming to improve animal health through science and technology.
The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian is a global animal health company headquartered in Stockholm, Sweden, focusing on four key areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company aims to provide innovative solutions for animal health professionals and pet owners, reaching over 17,000 veterinary clinics and laboratories in more than 80 markets, with 1,200 employees and annual revenues of approximately EUR 375 million.
YTD Price Performance: -27.09%
Average Trading Volume: 505,452
Technical Sentiment Signal: Sell
Current Market Cap: SEK15.26B
For an in-depth examination of VIMIAN stock, go to TipRanks’ Overview page.